Artemis Medicare Services Limited

rs,

Kurla Complex, Bandra (E), Mumbai – 400 051 The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 NSE Code: ARTEMISMED Scrip Code: 542919 Sub: Earnings Presenta

69.3%

H1 FY2024 Artemis Hospitals : At a Glance Established in July 2007 by promoters of Apollo Tyres (69.3% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR • 71

Rs. 2,250

8 Daffodils by Artemis Cardiac Centres 2 Financial Highlights – Q2 FY24 Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin

20%

by Artemis Cardiac Centres 2 Financial Highlights – Q2 FY24 Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY2

Rs. 366

iac Centres 2 Financial Highlights – Q2 FY24 Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4

47.2%

2 Financial Highlights – Q2 FY24 Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +

16.3%

cial Highlights – Q2 FY24 Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY

Rs. 135

Q2 FY24 Net Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY EBITDA Rs. 658 mn +41.7% Yo

54.4%

et Revenue Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY EBITDA Rs. 658 mn +41.7% YoY 15.1%

6.0%

Rs. 2,250 mn +20% YoY EBITDA Rs. 366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY EBITDA Rs. 658 mn +41.7% YoY 15.1% Margin N

Rs. 4,345

366 mn +47.2%YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY EBITDA Rs. 658 mn +41.7% YoY 15.1% Margin Net Profits Rs. 233 mn +36.7% YoY 5.4% Mar

22.5%

YoY 16.3% Margin Net Profits Rs. 135 mn 54.4% YoY 6.0% Margin H1 FY24 Net Revenue Rs. 4,345 mn +22.5% YoY EBITDA Rs. 658 mn +41.7% YoY 15.1% Margin Net Profits Rs. 233 mn +36.7% YoY 5.4% Margin Note

“As we move forward, we are pleased to share that the construction of our third tower is progressing as planned, and it is poised to contribute significantly to our efficiencies once it becomes operational in early FY25.”

Note

4

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations Dr. Devlina Chakravarty, Managing Director “Our results have yet again shown the strength of the Artemis brand and the patient experience which backs it. This is our best ever quarterly performance for the sixth consecutive quarter and is the result of our continuous efforts focussed on better revenue realisations and optimising operations. The quick occupancy ramp-up of our second tower has allowed us to reap the benefits of economies of scale, further enhancing our operational efficiency. As we move forward, we are pleased to share that the construction of our third tower is progressing as planned, and it is poised to contribute significantly to our efficiencies once it becomes operational in early FY25. During the quarter, we placed a strong emphasis on refining our case mix and payer mix, resulting in our highest ever ARPOB till date. Our revenue share from international patients for the quarter acc

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations 19 Q2 and H1 FY24 Financial Performance (Consolidated) (Rs. Million) Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisation expenses EBIT EBIT Margin Finance Cost PBT Total tax PAT PAT Margin

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations Q2 FY24 Q2 FY23 2,376.0 2,250.1 24.2 2,274.3 1,414.4 341.4 152.2 366.3 16.3% 99.5 266.8 11.9% 78.8 188.0 52.6 135.4 6.0% 1,963.6 1,874.6 14.1 1,888.7 1,185.1 300.8 154.0 248.9 13.3% 73.1 175.7 9.4% 49.0 126.7 39.0 87.7 4.7% YoY% 21.0% 20.0% 71.8% 20.4% 19.4% 13.5% (1.2%) 47.2% 36.1% 51.8% 60.9% 48.3% 34.7% 54.4% Q1 FY24 QoQ% H1 FY24 H1 FY23 2,202.0 2,095.4 12.5 2,107.9 1306.4 340.6 169.5 291.5 13.9% 91.7 199.8 9.5% 68.7 131.1 33.6 97.5 4.7% 7.9% 7.4% 93.8% 7.9% 8.3% 0.2% (10.2%) 25.7% 4,578.0 4,345.5 36.7 4,382.2 2720.8 681.9 321.7 657.8 15.1% 8.6% 191.2 33.5% 14.7% 43.4% 56.5% 38.8% 466.6 10.7% 147.6 319.1 86.2 232.9 5.4% 3,722.1 3,546.9 37.2 3,584.1 2243.0 584.3 292.7 464.1 13.1% 139.1 325.1 9.2% 92.2 232.9 62.5 170.4 4.8% YoY% 23.0% 22.5% (1.2%) 22.3% 21.3% 16.7% 9.9% 41.7% 37.5% 43.5% 60.0% 37.0% 37.9% 36.7% 20 Q2 and H1 FY24 Financial Performance (Standalone) (Rs. Million) Gross Revenue Net Revenue

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations 264.1 12.2% 74.8 189.4 51.7 137.7 6.3% 187.5 10.3% 46.4 141.1 43.1 98.0 5.4% YoY% 19.7% 18.9% 73.2% 19.3% 18.6% 12.7% 2.5% 39.1% 34.3% 40.9% 61.2% 34.2% 19.9% 40.5% Q1 FY24 QoQ% H1 FY24 H1 FY23 2,115.8 2,011.9 12.3 2,024.2 1254.2 326.3 158.7 284.9 14.2% 86.2 198.7 9.9% 64.8 133.9 34.5 99.4 4.9% 8.2% 7.8% 101.3% 8.4% 8.8% 0.6% (9.5%) 25.6% 4,405.6 4,181.0 37.1 4,218.1 2618.3 654.6 302.4 642.8 15.4% 8.8% 179.9 32.9% 15.4% 41.4% 49.8% 38.5% 462.8 11.1% 139.5 323.3 86.2 237.1 5.7% 3,634.1 3,459.1 37.0 3,496.0 2182.1 567.5 273.7 472.8 13.7% 132.5 340.2 9.8% 87.4 252.8 67.9 185.0 5.3% YoY% 21.2% 20.9% 0.3% 20.7% 20.0% 15.3% 10.5% 36.0% 35.7% 36.0% 59.7% 27.9% 27.0% 28.2% 21 Balance Sheet Overview Standalone Consolidated (Rs. Million) Particulars FY23 H1 FY 24 Particulars FY23 H1 FY24 Total Shareholders Funds 4,064 4,250 Total Shareholders Funds 4,077 4,276 Total Loans Other Long Term Liabilities / Provisions